Oracle Surges as US-China Reach TikTok Framework Deal: What It Means for the Company
Elutia’s Game-Changing Tech Has Boston Scientific’s Full Attention— Is A Bigger Deal Coming Next?
Elutia sells EluPro & CanGaroo assets to Boston Scientific for $88M, erasing debt and funding NXT-41—sparking speculation this divestiture could set the stage for a future full-company acquisition.
Consumer Sentiment Takes a Hit as Americans Worry About Jobs and Inflation
Stock Market Today: Dow Slips as S&P 500 and Nasdaq Hold Near Record Highs Ahead of Fed Decision
Zepp Health’s Bet On Women’s Health With The Wild.AI Buyout: Strategic Leap Or Risky Play?
Business & Market Movers
Vimeo’s $1.38 Billion Acquisition By Bending Spoons Isn’t Just A Buyout—It’s A Strategic Power Play!
·Sep 15, 2025
Stock Market Today: S&P 500 and Nasdaq Climb as Fed Decision Looms and Trade Talks Unfold
·Sep 15, 2025Breaking News
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”
Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled “Low Glycemic Sugar Composition” developed within this platform.
Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger
scdadmin·Dec 15, 2023
Deep Dive & Research
Healthcare & Biotech
Zepp Health’s Bet On Women’s Health With The Wild.AI Buyout: Strategic Leap Or Risky Play?
Zepp Health, best known for its Amazfit smartwatches, has taken a bold step in health-tech with its acquisition of Wild.AI’s core assets and IP—a leading platform in women’s wellness.
Phreesia’s $160 Million AccessOne Acquisition: Will This Deal Redefine Healthcare Payments?
Y-mAbs’ $412 Million Take-Private Offer From SERB Poised To Upset The Oncology Landscape
Merck’s $10 Billion Bet On Verona: Smart Strategic Pivot Or Costly Diversion From The Keytruda Cliff?
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here’s Why Zepbound Already Has a Giant Lead
DexCom’s Bold Type 2 Bet Could Reshape The Glucose Monitoring Market—What It Means for Investors!
Join our newsletter
Read and share new perspectives on just about any topic. Everyone’s welcome.- 01Create a free account
- 02Write your story
Tech & Energy
Elutia’s Game-Changing Tech Has Boston Scientific’s Full Attention— Is A Bigger Deal Coming Next?
Elutia sells EluPro & CanGaroo assets to Boston Scientific for $88M, erasing debt and funding NXT-41—sparking speculation this divestiture could set the stage for a future full-company acquisition.
